Market Cap
$1.9B
PGNY
Progyny, Inc.
$25.35 ▲ +2.01%
Prev close $24.85Market cap$1.9B
ConsensusStrong Buy
12-mo target$34.42 (+35.8%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (5 insiders)25 New Institutional Positions25 Institutional Exits Healthcare & Medical Devices
Snapshot
The big-picture read on PGNY right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (83%)
Inst. Holders
50 funds
Inst. Value
$1.8B
Inst. Activity
25 buys / 25 sells
Insider Activity
$0.00 buy / $1.3M sell
Insider Net $
-$1.3M
SEC Reports
12
Price chart 30d -3.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 23, 2026 Insider
Swartz Allison sold 3,903 shares
EVP, GC @ $26.10 ($101.9K)
Sep 17, 2026 Insider
Sep 10, 2026 SEC Clapp Geoffrey surrendered for taxes 819 shares
Chief Product Officer @ $27.38 ($22.4K)
Director Kevin K. Gordon filed a Form 144 notice of intent to sell 11,500 shares of Progyny, Inc. (PGNY) with an approxi
144 — Impact 2/10
Sep 10, 2026 Insider
GORDON KEVIN K acquired via exercise 22,000 shares
Director @ $13.00 ($286.0K)
Sep 8, 2026 short_volume
Jul 23, 2026 SEC Short Volume: PGNY — 68.5% short (0.5M / 0.7M)
Short: 467,834 | Exempt: 364 | TRF Vol: 682,781 | Short Ratio: 68.5% | Off-exchange volume (dark poo
Progyny issued a routine press release announcing the date of its Q2 2026 earnings call (August 6, 2026) and providing d
PRESS-RELEASE — Impact 2/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — NEW
1,785,717 shares ($51.5M)
Jun 30, 2026 Inst.
MORGAN STANLEY — TRIM
1,535,897 shares ($44.3M)
Analyst ratings buy % +16.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
83% rate it Buy or better · 18 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 30, 2026 | Wells Fargo | INITIATE | Overweight | 54% |
| Sep 8, 2026 | Citizens | MAINTAIN | Market Outperform | 38% |
| Aug 21, 2026 | JP Morgan | MAINTAIN | Neutral | 55% |
| Aug 20, 2026 | Wells Fargo | INITIATE | Overweight | 54% |
| Aug 13, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Aug 12, 2026 | Barclays | MAINTAIN | Equal-Weight | 54% |
| Jul 28, 2026 | Barclays | DOWNGRADE | Equal-Weight | 54% |
| Jul 24, 2026 | BTIG | MAINTAIN | Buy | 53% |
| Jul 21, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Jul 13, 2026 | Keybanc | MAINTAIN | Overweight | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 9 | 3 | 0 | 0 | 83% | |
| Aug 1, 2026 | 6 | 8 | 3 | 0 | 0 | 82% | |
| Jul 1, 2026 | 6 | 9 | 2 | 0 | 0 | 88% | |
| Jun 1, 2026 | 6 | 9 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 6 | 8 | 3 | 0 | 0 | 82% | |
| Apr 1, 2026 | 6 | 8 | 3 | 0 | 0 | 82% | |
| Mar 1, 2026 | 6 | 8 | 3 | 0 | 0 | 82% | |
| Feb 1, 2026 | 6 | 8 | 3 | 0 | 0 | 82% |
Price targets
Where 12 covering analysts think PGNY trades over the next 12 months.
$34.42 +35.8% upside Strong Buy
Current$25.35 Low$30.00 Median$35.00 High$40.00 12 analysts
$30.00$40.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 0 bullish, 2 bearish, 0 mixed, 10 neutral · avg impact 3.1/10.
NEUTRAL1442/10
Director Kevin K. Gordon filed a Form 144 notice of intent to sell 11,500 shares of Progyny, Inc. (P
Sep 10, 2026
NEUTRALPRESS-RELEASE2/10
Progyny issued a routine press release announcing the date of its Q2 2026 earnings call (August 6, 2
Jul 23, 2026
BEARISHINST-CLUSTER5/10
Significant institutional divergence in PGNY during Q3 2024: 23 buyers (net +$5.2M) faced off agains
Jun 12, 2026
NEUTRALCLUSTER3/10
Four Progyny insiders (CEO excluded) sold a total of ~$402K worth of common stock over a 7-day windo
Jun 5, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 8, 2026
short_volume
Short Volume: PGNY — 68.5% short (0.5M / 0.7M)
Short: 467,834 | Exempt: 364 | TRF Vol: 682,781 | Short Ratio: 68.5% | Off-exchange volume (dark pool + OTC)
Aug 7, 2026
other
Progyny, Inc. to Present at the Canaccord Genuity Annual Growth Conference
NEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today annou
Aug 7, 2026
short_volume
Short Volume: PGNY — 60.7% short (0.6M / 1.1M)
Short: 643,125 | Exempt: 27,615 | TRF Vol: 1,059,027 | Short Ratio: 60.7% | Off-exchange volume (dark pool + OTC)
Aug 6, 2026
earnings
Progyny, Inc. Announces Second Quarter 2026 Results
Reports Record Quarterly Revenue, Gross Profit and Adjusted EBITDA Robust Selling Season Activity Continues to Reflect Strong Demand for Women's Healt
Aug 6, 2026
earnings_calendar
PGNY Q2 2026 Earnings Scheduled — 2026-08-06
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.51 | $0.49–$0.53 | 13.1% | -1.7% | 1↑ 6↓ | $0.3B | 9 |
| Next Q | $0.53 | $0.51–$0.54 | 9.7% | +0.8% | 6↑ 1↓ | $0.4B | 9 |
| Current FY | $2.08 | $2.06–$2.10 | 10.3% | +0.4% | 8↑ 0↓ | $1.4B | 9 |
| Next FY | $2.32 | $2.18–$2.47 | 11.3% | +2.1% | 7↑ 1↓ | $1.5B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.509 | — |
| 7d ago | $0.509 | — |
| 30d ago | $0.518 | -0.009 |
| 60d ago | $0.523 | -0.014 |
| 90d ago | $0.523 | -0.014 |
Institutional ownership
Which big funds own PGNY (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $1.8B total value (61,491,730 shares) as of 2026-Q2. Top holders: BlackRock,, FMR, VANGUARD.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 11,599,921 | $334.4M | 18.9% | — |
| FMR LLC | 7,004,280 | $201.9M | 11.4% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5,019,465 | $144.7M | 8.2% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 3,210,723 | $92.6M | 5.2% | — |
| STATE STREET CORP | 3,022,859 | $87.1M | 4.9% | — |
| AMERIPRISE FINANCIAL INC | 2,763,514 | $79.7M | 4.5% | — |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | 2,548,164 | $73.5M | 4.1% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,969,208 | $56.8M | 3.2% | — |
| CITADEL ADVISORS LLC | 1,785,717 | $51.5M | 2.9% | NEW |
| DIMENSIONAL FUND ADVISORS LP | 1,688,670 | $48.7M | 2.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | NEW | — | 1,785,717 | — | $51.5M |
| MORGAN STANLEY | TRIM | 2,287,617 | 1,535,897 | -32.9% | $44.3M |
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | 2,287,381 | 1,496,633 | -34.6% | $43.1M |
| JANE STREET GROUP, LLC | DOUBLED | 148,906 | 1,063,363 | +614.1% | $30.7M |
| AMERICAN CENTURY COMPANIES INC | DOUBLED | 225,792 | 778,839 | +244.9% | $22.5M |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,190,996 | 598,815 | -49.7% | $17.3M |
| DANSKE BANK A/S | ADD | 415,186 | 528,717 | +27.3% | $15.2M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 74,692 | 439,622 | +488.6% | $12.7M |
| JPMORGAN CHASE & CO | TRIM | 680,325 | 429,868 | -36.8% | $12.5M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 812,067 | 424,667 | -47.7% | $12.2M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 50 transactions. Net -$1.3M — $0.00 bought, $1.3M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Swartz Allison | EVP, GC | SELL | 3,903 | $26.10 | $101.9K |
| Sep 17, 2026 | Clapp Geoffrey | Chief Product Officer | TAX W/H | 819 | $27.38 | $22.4K |
| Sep 10, 2026 | GORDON KEVIN K | Director | EXERCISE | 22,000 | $13.00 | $286.0K |
| Sep 10, 2026 | GORDON KEVIN K | Director | TAX W/H | 10,500 | $27.24 | $286.0K |
| Sep 10, 2026 | GORDON KEVIN K | Director | SELL | 11,500 | $27.94 | $321.4K |
| Sep 10, 2026 | GORDON KEVIN K | Director | EXERCISE | 22,000 | $13.00 | $286.0K |
| Sep 10, 2026 | GORDON KEVIN K | Director | TAX W/H | 10,500 | $27.24 | $286.0K |
| Sep 10, 2026 | GORDON KEVIN K | Director | SELL | 11,500 | $27.12 | $311.9K |
| Sep 4, 2026 | Livingston Mark S. | CHIEF FINANCIAL OFFICER | TAX W/H | 479 | $26.61 | $12.7K |
| Sep 4, 2026 | Swartz Allison | EVP, GC | TAX W/H | 479 | $26.61 | $12.7K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PGNY.
Shares short
4,707,672
Settlement Sep 15, 2026
Change vs prior
+5.8%
Semi-monthly cycle
Days to cover
4.6
At avg daily volume
Of shares outstanding
≈6.1%
Estimate — not % of float
All PGNY filing & press-release reports (12)
- 144 reportSep 10, 2026
- PRESS-RELEASE reportJul 23, 2026
- INST-CLUSTER reportJun 12, 2026
- CLUSTER reportJun 5, 2026
- CLUSTER reportJun 3, 2026
- PRESS-RELEASE reportMay 28, 2026
- 144 reportMay 27, 2026
- CLUSTER reportMay 26, 2026
- 8-K reportMay 26, 2026
- CLUSTER reportMay 21, 2026
- PRESS-RELEASE reportApr 23, 2026
- DEFA14A reportApr 10, 2026